Niclosamide vs Methylene Blue for Spike Protein Disease (2025)

By Editorial Team -
Spike protein disease refers to the pathological effects of the SARS-CoV-2 spike protein, including acute infection via ACE2 receptor binding, syncytia formation, and chronic sequelae like oxidative stress, inflammation, mitochondrial dysfunction, and cytokine storms. Both niclosamide (an FDA-approved anthelmintic) and methylene blue (an FDA-approved redox agent) are repurposed drugs with antiviral properties against SARS-CoV-2, including variants like Omicron. They target different aspects of spike-mediated pathology: methylene blue excels in direct spike inhibition and toxicity mitigation, while niclosamide focuses on viral entry and clearance. Below is a structured comparison based on preclinical and clinical data as of September 2025.

Niclosamide vs Methylene Blue for Spike Protein Disease

  • Primary Mechanisms
    • Niclosamide: Acts as a protonophore to neutralize endosomal pH, blocking viral internalization and replication. Inhibits TMEM16 proteins, preventing spike-induced syncytia formation and platelet activation. Targets CD147 receptor to restrict spike entry. Reduces infectious progeny release in organoids without affecting genome replication.
    • Methylene Blue: Directly binds spike protein, inhibiting spike-ACE2 interaction (IC50 ~3 μM) and shielding cell surfaces via heparan sulfate proteoglycans. Inhibits post-replication progeny release in organoids. Mitigates toxicity via redox modulation: reduces ROS, iNOS/NO, NF-κB signaling; enhances mitochondrial ETC and SIRT1/PGC-1α for antioxidant effects; curbs cytokine storms and inflammasome activation.
  • Preclinical Efficacy (Spike/Omicron Focus)
    • Niclosamide: Effective against Omicron BA.1 in airway organoids (5-10 μM reduces titers by ~2 log10; toxic at 20 μM). Blocks spike-induced syncytia and entry in cell models; broad antiviral at micromolar doses.
    • Methylene Blue: Strong Omicron inhibition in organoids (10 μM reduces infection to ~6%). Low-micromolar block of spike-ACE2 (IC50 3-3.5 μM); virucidal against SARS-CoV-2 and variants.
  • Clinical Efficacy
    • Niclosamide: 2025 RCT (n=300, mild-moderate COVID): Low dose (300 mg) shortens symptoms (9 vs. 13 days, p=0.008) and accelerates viral clearance (56% reduction at 16h vs. 4% placebo). Meta-analysis (7 RCTs, >2,000 pts): 28% lower serious outcomes (p=0.0077); 29% improved early recovery, 12% lower mortality. Limited data on chronic toxicity relief.
    • Methylene Blue: 2024 RCT (n=122, COVID-ARDS): Improves SpO2 (+6.42%, p=0.022), CRP, and APACHE II scores; no mortality/hospitalization benefit. Mixed trials (up to 2023): Some show reduced hospitalization/mortality (e.g., 60% recovery in hypoxic pts); trends in shorter stays with nebulized MB. Stronger evidence for toxicity relief (e.g., hypoxemia, inflammation) but inconsistent viral clearance.
  • Safety & Dosing
    • Niclosamide: Mild AEs (e.g., GI upset at high doses); no serious events in trials. Oral: 300-600 mg/day; well-tolerated but monitor for toxicity at >10 μM in vitro.
    • Methylene Blue: Safe at therapeutic doses; mild AEs (e.g., urine discoloration). Oral/IV/nebulized: 1-2 mg/kg; avoid with SSRIs (serotonin risk).
  • Availability & Cost
    • Niclosamide: Inexpensive (~$0.10/dose); oral tablets widely available.
    • Methylene Blue: Very cheap (~$0.05/dose); oral/IV forms readily accessible.
Key Insights
  • For Acute Spike-Mediated Infection: Niclosamide shows superior viral clearance and entry blockade in recent trials, making it potentially better for early intervention to prevent spike persistence.
  • For Chronic Toxicity/Sequelae: Methylene blue is closer to an "antidote" due to its multifaceted relief of redox imbalance, inflammation, and mitochondrial issues—core drivers of long COVID-like symptoms.
  • Head-to-Head: No direct comparative trials exist, but both inhibit Omicron similarly in organoids, suggesting complementary use (e.g., niclosamide for clearance + MB for detox). Neither is approved for COVID-19, and evidence remains preliminary—consult a physician for off-label use. Ongoing trials may clarify roles by late 2025.

Comments

Post a Comment

Popular posts from this blog

Dr Peter McCullough: How to Detox Spike Protein from Body

By Editorial Team -
Image
Base Spike Detox According to Dr Peter McCullough (in a X/Twitter post): Base Spike Detox is what I am currently using in my practice for those who have had COVID-19 multiple times, one or more of the COVID-19 vaccines, or both and believe persistent SARS-CoV-2 Spike protein could be causing problems in their body.  I have arrived, based on the emerging scientific literature (1) and my clinical observation, that three OTC products are essential as a triple base combination: Nattokinase 2000 FU (100 mg) twice a day Bromelain 500 mg once a day Nano/Liposomal Curcumin 500 mg twice a day Related: Nattokinase, Bromelain and Curcumin from The Wellness Company Additional products can be added, including NAC, IVM (Ivermectin), HCQ (Hydroxychloroquine), fluvoxamine, low-dose naltrexone, and blood thinners, depending on the clinical evaluation and the syndrome. The therapeut...
Read more

Front Line Doctors Ivermectin Protocol for Prevention and Treatment of COVID-19 (2025)

By Editorial Team -
Image
The Front Line COVID-19 Critical Care (FLCCC*) Alliance was initially formed as a working group during the early COVID-19 pandemic days in response to multiple early reports of COVID patients with an inexplicably high need for prolonged mechanical ventilation and an excessive death rate.  *The FLCCC Alliance is now the  Independent Medical Alliance Based on rapidly emerging clinical trials evidence, the FLCCC team has developed the   I-MASK+ protocol   ( is now divided into I-Prevent and I-Care protocols ) for prophylaxis and at home treatment of early stage COVID-19. Quercetin, zinc and a number of nutrients and drugs are part of this protocol, not only for critical care but also for prophylaxis and mild disease being treated at home. This article, we will dive deeper to provide the scientific background, related references and rationale of the FLCCC protocols. Update:  NB.1.8.1 COVID variant: Symptoms, Spread, and What You Need to Know  (June 2025) FLCCC ...
Read more

FLCCC I-CARE COVID Treatment Protocol for Outpatients (2025 Edition)

By Editorial Team -
Image
Early treatment is critical and the most important factor in managing this disease. COVID-19 is a clinical diagnosis; a confirmed antigen or PCR test is not required. Treatment should be initiated immediately after the onset of flu-like symptoms. The multiple therapies and drugs in this protocol have different mechanisms of action and work synergistically during various phases of the disease. About I-CARE Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. Updates:  The Stratus Variant (XFG): Symptoms, Global Spread, and Impact in Late 2025 Note: According to Dr Pierre Kory, "...highlighting his objectivity, while Pierre Kory was once the leading advocate for ivermectin to treat COVID, he no longer does as the newer vari...
Read more

How to Remove Spike Protein from Body: FLCCC I-Recover Protocol

By Editorial Team -
Image
Can you remove spike proteins from your body? Dr. Paul Marik and Dr. Pierre Kory are pleased to introduce the I-RECOVER: Post-Vaccine Treatment protocol, designed to help people who have experienced adverse symptoms after a COVID vaccine. Kory and Marik are both part of the FLCCC*, which was founded in 2020 to share early treatment protocols for COVID-19. Kory is an ICU specialist, triple board certified in internal medicine, critical care and pulmonary medicine. He now runs a private tele-health practice specializing in the treatment of COVID-19, so-called "long-COVID" and post-vaccine syndrome. *The FLCCC Alliance is now the  Independent Medical Alliance Note that there are significant overlaps between the symptoms and features of long COVID/long-hauler syndrome and post-vaccine syndrome. However, a number of clinical features appear to be characteristic of post-vaccine syndrome; most notably, severe neurological symptoms appear to be more common following vaccination. To c...
Read more

FLCCC I-Recover Protocol: Post Vaccine Treatment Protocol (2025)

By Editorial Team -
Image
Over the last three years, the COVID-19 pandemic has transformed almost every aspect of our lives before we've had time to stop and question it. Although no official definition exists for post-COVID-vaccine syndrome, a temporal correlation between a patient receiving a COVID-19 vaccine and beginning or worsening of clinical manifestations is sufficient to diagnose as a COVID-19 vaccine-induced injury, when the symptoms are unexplained by other concurrent causes. Dr. Paul Marik and Dr. Pierre Kory are pleased to introduce the I-RECOVER: Post-Vaccine Treatment protocol, designed to help people who have experienced adverse symptoms after a COVID vaccine. Kory and Marik are both part of the FLCCC (The FLCCC Alliance is now the Independent Medical Alliance ), which was founded in 2020 to share early treatment protocols for COVID-19. Kory is an ICU specialist, triple board certified in internal medicine, critical care and pulmonary medicine. He now runs a privat...
Read more

Turbo Cancers on the Rise: 2025 Studies and Updates

By Editorial Team -
Image
A sudden rise in younger people with early onset cancers which are more aggressive with more (and unusual) genetic change has been increasingly noted - colorectal, breast and GI tract cancers seem to lead the way. New Study Defines Mechanisms of Post-mRNA Vaccine “Turbo Cancer” Peer-reviewed research from Drs. Paul Marik and Justus Hope links COVID-19 mRNA vaccines to “turbo cancer,” detailing five biological pathways that may drive aggressive, fast-growing cancers. Dr. Paul Marik, chief scientific officer and co-founder of the Independent Medical Alliance, isn’t one to shy away from hard truths. In his video statement below, accompanying the release of a new peer-reviewed paper , he described what doctors and nurses around the world have been seeing since 2021: more aggressive cancers, affecting younger patients, and returning with a vengeance in people once in remission — often within weeks of a COVID-19 booster shot. The paper, co-authored ...
Read more

Dr Peter McCullough Early Treatment Protocol

By Editorial Team -
Image
Well-respected North Texas cardiologist, Dr. Peter McCullough has impeccable academic credentials. He's an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. McCullough et al. Reviews in Cardiovascular Medicine, 2020 McCullough Protocol 2022 Updates:  How to Detox Spike Protein from Body  (November 2023) Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2 (October 2024) Paxlovid for Vaccinated or Unvaccinated Adult Outpatients with ...
Read more

Find a Doctor to prescribe Hydroxychloroquine, Ivermectin and Early Outpatient Treatments (2025)

By Editorial Team -
Image
Treatment should start based on clinical suspicion as soon as possible, preferably within the first 3 days of symptoms. Perform PCR testing, but do not withhold treatment pending results. 'Early' treatment will make significant difference in outcome as opposed to late treatment.  Related: How can I get Ivermectin? See the directory of professionals in US below. Directory of Doctors (by State) Prescribing Effective Outpatient COVID-19 Therapy USA ​ MULTIPLE STATES (Telemedicine or online consultation) The Wellness Company ( twc.health ) Medical Specialty: Family Medicine, Functional Medicine Supported Protocols: I-PREVENT (COVID Protection), I-CARE (Early at-home treatment), I-RECOVER (Long COVID and Post-Vaccine treatment) Dr. Miguel Antonatos (IVM) (855) 767-8559  https://text2md.com (States: AL, AZ, CO, FL, GA, IA, ID, IL, KS, KY, MD, ME, MI, MN, MS, ND, NE, NJ, NV, OK, SC, SD, TN, UT, VT, WA, WI, WV) ...
Read more

What if Niacinamide Held the Key to Long COVID Recovery? (2025)

By Editorial Team -
Image
If you've had COVID-19 or know someone who has, you've likely seen how the illness lingers. Unresolved fatigue, reduced physical capacity, and cognitive fog are common weeks or even months after the infection clears. In more severe cases, the virus left behind lasting damage to the kidneys, lungs, or vascular system. These outcomes are now recognized as long COVID. As attention shifts from short-term containment to long-term recovery, more researchers are focusing on the cellular pathways that support resilience after viral illness. One area drawing renewed attention is the use of nicotinamide adenine dinucleotide (NAD⁺), a molecule your cells use to produce energy, repair DNA, regulate inflammation, and maintain mitochondrial function. One of the most straightforward ways to raise NAD⁺ safely and effectively is through niacinamide, a common and inexpensive form of vitamin B3. Case in point, a new placebo-controlled trial published in Nature Metabolism has highlighted niacinami...
Read more

COVID-19 Variant NB.1.8.1 (Nimbus): Symptoms (Razor Blade Throat), Spread, and Impact in 2025

By Editorial Team -
Image
Overview A new COVID-19 variant, identified as NB.1.8.1, has recently emerged and is drawing international attention due to its increasing prevalence, particularly in China, and its detection in the United States and other countries. September 2025 Update: The Stratus Variant (XFG): Symptoms, Global Spread, and Impact in Late 2025 1. Emergence and Spread of NB.1.8.1 Origin and Detection: NB.1.8.1 was first identified as a significant driver of rising COVID-19 cases in China. The U.S. Centers for Disease Control and Prevention (CDC) confirmed its presence in the United States, though as of late May 2025, fewer than 20 cases had been reported domestically. Global Spread: The World Health Organization (WHO) and multiple health authorities have noted that NB.1.8.1 is now spreading worldwide, with cases reported in several countries. Its rapid dissemination has raised concerns about potential increases in COVID-19 cases in various regions. 2. Variant Characteristics Genetic Profile: NB.1.8....
Read more

Labels

Show more

Archive

Show more